Side-Effects Management
Based on research presented at the 2018 National Comprehensive Cancer Network Annual Conference, patients weighing 60 kg to 85 kg who often receive lower-than-recommended doses of filgrastim, without evidence of its noninferiority to recommended doses, is found to be not only acceptable, but also cost-saving.
At the 2018 Cancer Survivorship Symposium, Katy K. Tsai, MD, suggested that cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint because of its novel mechanisms of action, extended treatment periods, and unique toxicities.
Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.
Results 1 - 6 of 6